CN1559423A - Oral effervesce tablets for treating cardiovascular and cerebrovascular diseases, and prepn. method therefor - Google Patents
Oral effervesce tablets for treating cardiovascular and cerebrovascular diseases, and prepn. method therefor Download PDFInfo
- Publication number
- CN1559423A CN1559423A CNA2004100165104A CN200410016510A CN1559423A CN 1559423 A CN1559423 A CN 1559423A CN A2004100165104 A CNA2004100165104 A CN A2004100165104A CN 200410016510 A CN200410016510 A CN 200410016510A CN 1559423 A CN1559423 A CN 1559423A
- Authority
- CN
- China
- Prior art keywords
- effervescent
- breviscapine
- oral cavity
- tablet
- effervescent tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
A oral-cavity effervescent talbet for treating cardiovascular and cerebrovascular diseases, such as coronary heart disease, angina pectoris, cerebral thrombosis, cerebral infarction, etc. is prepared from breviscapine, diluent, disintegrant, effervescent agent, flavouring, flowing aid,and lubricant.
Description
Technical field
The invention belongs to technical field of pharmaceuticals, relate to a kind of oral cavity effervescent tablet for the treatment of the heart, cerebrovascular disease, being specifically related to main component is oral cavity effervescent tablet of breviscapine and preparation method thereof.
Background technology
Breviscapine is the total flavonoids substance that extracts by in the short fluffy plant of Roripa second [Erigron breviscapus (Vaniot) Hand Mazz] Herba Erigerontis of Compositae, has blood circulation promoting and blood stasis dispelling, dilating coronary blood vessel, cerebrovascular effect, can improve the symptom of the heart, cerebral ischemia generation, be usually used in cardiovascular diseases such as coronary heart disease, angina pectoris, cerebral thrombosis, cerebral infarction the curative of paralysis extremely etc.Be usually used in clinical common Herba Erigerontis tablet at present, though curative effect is more definite, exist dissolution rate slow, stripping quantity is few, the defectives such as inconvenience of swallowing.Preparation with the breviscapine prescription commonly used also has oral formulations such as slow releasing tablet, dispersible tablet, drop pill, capsule, but does not still have the preparation of effervescence type in the oral cavity.
Owing to reasons such as technologies of preparing, have after most of oral formulations are taken that dissolve scattered time limit is long, dissolution is low, absorption is relatively poor, a problem such as liver sausage first pass effect and bioavailability are lower, thereby influence the performance of drug effect, also directly affect the effect of treatment.According to the document introduction of relevant drop pill, though said preparation also has the high advantage of bioavailability, its dissolve scattered time limit still is＜30min.In addition, other oral formulations needs a large amount of water to send down when taking, and makes the patient of many old peoples, infant or dysphagia, water intaking inconvenience be difficult to take.
It is reported that U.S. FDA has been examined two Western medicine effervescence type oral cavity disintegration tablets: Zolmitriptan (Zomig-ZMT, Astra-Zeneca) and Minaprine (Romeron Soltab, Organon).The oral cavity effervescent tablet belongs to the scope of " oral cavity disintegration tablet ", not needing to be characterized in water to swallow, direct effervescent in the oral cavity, to the oral mucosa nonirritant, mouthfeel is good, can also be in the oral cavity stripping part medicine, produce certain absorption, and in digestive tract in the transport process, lysed medicine directly contacts also with gastrointestinal mucosal can produce absorption, make drug absorption more complete, can improve bioavailability of medicament.The disintegrate of oral cavity effervescent tablet generally in 30 seconds, is no more than 1 minute at most.And the dissolve scattered time limit of drop pill Chinese Pharmacopoeia regulation is in 30 minutes, and conventional tablet Chinese Pharmacopoeia regulation disintegration is all molten loosing about 5 minutes.
Breviscapine is the flavonoid glycoside structure, be an insoluble drug, warp is to the marketed tablet drug release determination, and the result is its stripping quantity 80% in 1.5 hours, and stripping in 45 minutes is about 70%, therefore Herba Erigerontis tablet not only has a disintegrate problem, and the process of stripping is more arranged, and because breviscapine is insoluble to tart gastric juice, behind oral its tablet, even rapid under one's belt effervescent seldom discharges breviscapine, so there is the problem of infiltration rate and bioavailability in its solid preparation in gastric juice.Ding Jiangsheng etc. have carried out the research of breviscapine rat small intestine absorption characteristic, the result proves: breviscapine mainly absorbs with passive diffusion way at rat small intestine, improving drug solubility adopts short absorption process to improve permeability, can promote the absorption of breviscapine effectively, reach the purpose that improves bioavailability; Experiment is proof also: breviscapine all has absorption (China Medicine University's journal at whole intestinal segment; 2003,34 (1): 65～69).
Summary of the invention
The purpose of this invention is to provide a kind of oral cavity effervescent tablet pharmaceutical preparation for the treatment of the heart, cerebrovascular disease, be specifically related to a kind of oral cavity effervescent tablet that contains breviscapine and preparation method thereof.It is the deficiency of the preparation of main medicine prescription with breviscapine that oral cavity of the present invention effervescent tablet can replenish existing, for coronary heart disease, angina pectoris, cerebral thrombosis, cerebral infarction the patient of diseases such as paralysis extremely provide that a kind of absorption is fast, bioavailability is high, intestinal is residual few, side effect is low, avoid liver first-pass effect, and needn't drink water, be rapid effervescent or dissolving in the oral cavity, the breviscapine oral effervescent tablet of taking convenience.
Oral cavity provided by the invention effervescent tablet, (also claim lamp-dish flower acetic with breviscapine, commercial) be main component, be equipped with adjuvants such as diluent, disintegrating agent, effervescent, correctives, lubricant, fluidizer, binding agent, be prepared from through the tablet producing technology of routine.
Diluent of the present invention comprises pre-paying starch, cross-linked pvp, mannitol and lactose, described disintegrating agent comprises pre-paying starch, HPMC and L-HPC, described binding agent comprises polysaccharide and cellulose families such as HPMC, L-HPC such as starch, effervescent comprises sodium bicarbonate and tartaric acid, sodium bicarbonate and citric acid, sodium bicarbonate and fumaric acid, sodium bicarbonate and vitamin C, correctives comprises acesulfame potassium, A Siba is sweet and cyclamate, lubricant comprises magnesium stearate, Pulvis Talci and sodium lauryl sulphate, and fluidizer is micropowder silica gel.
Each constituent content (every) of breviscapine oral effervescent tablet of the present invention is,
Breviscapine 20～40mg,
Diluent 20～100mg,
Disintegrating agent 2～40mg,
Effervescent 5～50mg,
Correctives 3～20mg,
Lubricant 2～10mg mg,
Fluidizer 5～10mg,
Adhesive 0～30mg.
Wherein, the visual concrete condition of adhesive is selected to use, diluent can be selected pre-paying starch for use, cross-linked pvp, mannitol, monosaccharide such as lactose, disaccharidase, the mixture that polysaccharide etc. are any or two or more, effervescent can be selected pre-paying starch for use, the mixture that synthetic cellulose etc. are any or two or more, effervescent can be selected sodium bicarbonate and tartaric acid or citric acid or fumaric acid or Vitamin C mixture for use, correctives can be selected acesulfame potassium for use, A Siba is sweet, the mixture that cyclamate etc. are any or two or more, lubricant can be selected magnesium stearate for use, the mixture that Pulvis Talci is any or two or more, described fluidizer is micropowder silica gel, and binding agent is cellulose substances such as polysaccharides such as starch and HPMC.
Breviscapine oral effervescent tablet of the present invention can prepare by following direct powder compression or wet granule compression tablet method,
1, direct powder compression
1. press component dosage, correctly take by weighing each former, adjuvant;
2. breviscapine and each diluent, effervescent are dried back pulverizing, sieving for standby respectively;
3. with effervescent respectively at below 45 ℃ the oven dry, sieving for standby behind the pulverizing;
4. breviscapine and each adjuvant except that lubricant, fluidizer are with the equivalent method mix homogeneously that progressively increases;
5. add lubricant and fluidizer, mix homogeneously, gained direct powder compression.
2, wet granule compression tablet method
1. the component dosage that requires according to prescription correctly takes by weighing each former, adjuvant;
2. breviscapine and each diluent, effervescent are dried back pulverizing, sieving for standby respectively;
3. with effervescent respectively at below 45 ℃ the oven dry, sieving for standby behind the pulverizing;
4. breviscapine and other each adjuvant except that effervescent are with the equivalent method mix homogeneously that progressively increases;
5. above mixed material is divided into two parts, respectively with sodium bicarbonate and sour mix homogeneously after, granulate with 65～75% ethanol, under 40～55 ℃ condition, dry, granulate, add lubricant after tabletting promptly.
Oral cavity of the present invention effervescent tablet, put into the not only very fast effervescent disintegrate of mouth, owing to contain sodium bicarbonate in the prescription, make Herba Erigerontis tablet saliva on every side become alkalescence, breviscapine is along with the effervescent disintegrate of tablet, part just is dissolved in the saliva, drug molecule spreads to oral mucosa on the one hand, generation partially absorbs, unabsorbed on the other hand drug molecule is along with swallowing of saliva enters in the gastro-intestinal Fluid together, can be directly from solution, produce and absorb to the gastrointestinal mucosal diffusion, thus absorb fast and complete, bioavailability is high, can further improve clinical efficacy.
Through prescription screening, factors influencing and 40 ℃ of RH75% and 6 months study on the stability of room temperature (25 ℃ ± 2 ℃), oral cavity of the present invention effervescent tablet stable in properties.
Breviscapine oral effervescent tablet of the present invention, have absorb fast, bioavailability is high, intestinal is residual few, side effect is low, avoids good characteristics such as liver first-pass effect and taking convenience, clinically is used for diseases such as apoplexy sequela, coronary heart disease, angina pectoris, the patient mainly is the old people, and is with the apoplexy sequela patient, handicapped especially, dysphagia, therefore, oral cavity of the present invention effervescent tablet, need not swallow, being placed on has saliva to get final product effervescent in the oral cavity, taking convenience, and therapeutic effect is obvious.
The specific embodiment
Below with specific embodiment to of the present invention and breviscapine oral effervescent tablet technical scheme be described further.
Embodiment 1
Component:
Raw material---breviscapine 20g;
Diluent---mannitol 100g, crospolyvinylpyrrolidone 20g, lactose 100g;
Disintegrating agent---partially pregelatinized starch (kind reaching) 8.5g;
Effervescent---sodium bicarbonate 20g, tartaric acid 16g;
Fluidizer---micropowder silica gel 10g;
Correctives---Fructus Citri Limoniae essence 5g; Aspartame 1.5g;
Lubricant---magnesium stearate 4g.
The preparation of employing direct powder compression,
The first step correctly takes by weighing each former, adjuvant by above-mentioned component dosage, adds up to weight 305g;
Second step was ground breviscapine, crossed 100 mesh sieves; Mannitol, partially pregelatinized starch (kind reaching), lactose are respectively at 45 ℃ of oven dry, and it is standby that pulverizing is crossed 100 mesh sieves;
The 3rd step dried sodium bicarbonate, tartaric acid down respectively at 45 ℃, pulverizing, and it is standby to cross 100 mesh sieves;
Adjuvants such as the 4th step breviscapine and partially pregelatinized starch, sodium bicarbonate, tartaric acid, crospolyvinylpyrrolidone, Fructus Citri Limoniae essence, aspartame are with the equivalent method mix homogeneously that progressively increases;
The 5th step added magnesium stearate and micropowder silica gel, and mix homogeneously adopts THP flower basket type tablet machine and diameter 8mm punch die direct compression.Make 1000 altogether, every heavy 305mg contains breviscapine 20mg.
Embodiment 2
Component:
Raw material---breviscapine 20g;
Diluent---mannitol 100g, crospolyvinylpyrrolidone 20g, lactose 100g;
Effervescent---partially pregelatinized starch (kind reaching) 8.5g;
Effervescent---sodium bicarbonate 20g, citric acid 16g;
Fluidizer---micropowder silica gel 10g;
Correctives---Fructus Citri Limoniae essence 5g; Aspartame 1.5g;
Lubricant---magnesium stearate 4g.
The preparation of employing direct powder compression,
The first step correctly takes by weighing each former, adjuvant according to the component dosage that prescription requires, and adds up to weight 305g;
Second step was ground breviscapine, crossed 100 mesh sieves; Mannitol, partially pregelatinized starch (kind reaching), lactose are respectively at 45 ℃ of oven dry, and it is standby that pulverizing is crossed 100 mesh sieves;
The 3rd step dried sodium bicarbonate, citric acid down respectively at 45 ℃, pulverizing, and it is standby to cross 100 mesh sieves;
Adjuvants such as the 4th step breviscapine and lactose, partially pregelatinized starch, sodium bicarbonate, citric acid, crospolyvinylpyrrolidone, Fructus Citri Limoniae essence, aspartame are with the equivalent method mix homogeneously that progressively increases;
The 5th step added magnesium stearate and micropowder silica gel, and mix homogeneously adopts THP flower basket type tablet machine and diameter 8mm punch die direct compression.Make 1000 altogether, every heavy 305mg contains breviscapine 20mg.
Embodiment 3
Component:
Raw material---breviscapine 20g;
Diluent---mannitol 100g, crospolyvinylpyrrolidone 10g, lactose 100g;
Disintegrating agent---partially pregelatinized starch (kind reaching) 8.5g;
Effervescent---sodium bicarbonate 20g, fumaric acid 16g;
Fluidizer---micropowder silica gel 10g;
Correctives---Fructus Citri Limoniae essence 5g; Aspartame 1.5g;
Lubricant---magnesium stearate 4g.
The preparation of employing direct powder compression,
The first step correctly takes by weighing each former, adjuvant according to the component dosage that prescription requires, and adds up to weight 305g;
Second step was ground breviscapine, crossed 100 mesh sieves; Mannitol, partially pregelatinized starch (kind reaching), lactose are respectively at 45 ℃ of oven dry, and it is standby that pulverizing is crossed 100 mesh sieves;
The 3rd step dried sodium bicarbonate, fumaric acid down respectively at 45 ℃, pulverizing, and it is standby to cross 100 mesh sieves;
Adjuvants such as the 4th step breviscapine and lactose, partially pregelatinized starch, sodium bicarbonate, fumaric acid, crospolyvinylpyrrolidone, Fructus Citri Limoniae essence, aspartame are with the equivalent method mix homogeneously that progressively increases;
The 5th step added magnesium stearate and micropowder silica gel, and mix homogeneously adopts THP flower basket type tablet machine and diameter 8mm punch die direct compression.Make 1000 altogether, every heavy 305mg contains breviscapine 20mg.
Embodiment 4
Component:
Raw material---breviscapine 20g;
Diluent---mannitol 100g, crospolyvinylpyrrolidone 10g, lactose 100g;
Disintegrating agent---partially pregelatinized starch (kind reaching) 8.5g;
Effervescent---sodium bicarbonate 20g, vitamin C 16g;
Fluidizer---micropowder silica gel 10g;
Correctives---Fructus Citri Limoniae essence 5g; Aspartame 1.5g;
Lubricant---magnesium stearate 4g.
The preparation of employing direct powder compression.
The first step correctly takes by weighing each former, adjuvant according to the component dosage that prescription requires, and adds up to weight 305g;
Second step was ground breviscapine, crossed 100 mesh sieves; Mannitol, partially pregelatinized starch (kind reaching), lactose are respectively at 45 ℃ of oven dry, and it is standby that pulverizing is crossed 100 mesh sieves;
The 3rd step dried sodium bicarbonate, vitamin C down respectively at 45 ℃, pulverizing, and it is standby to cross 100 mesh sieves;
Adjuvants such as the 4th step breviscapine and lactose, partially pregelatinized starch, lactose, sodium bicarbonate, vitamin C, crospolyvinylpyrrolidone, Fructus Citri Limoniae essence, aspartame are with the equivalent method mix homogeneously that progressively increases;
The 5th step added magnesium stearate and micropowder silica gel, and mix homogeneously adopts THP flower basket type tablet machine and diameter 8mm punch die direct compression.Make 1000 altogether, every heavy 305mg contains breviscapine 20mg.
Embodiment 5
Component:
Raw material---breviscapine 20g;
Diluent---mannitol 100g, crospolyvinylpyrrolidone 10g, lactose 100g;
Disintegrating agent---partially pregelatinized starch (kind reaching) 8.5g;
Effervescent---sodium bicarbonate 20g, citric acid 16g;
Fluidizer---micropowder silica gel 10g;
Correctives---Fructus Citri Limoniae essence 5g; Aspartame 1.5g;
Lubricant---magnesium stearate 4g.
Adopt the preparation of wet granule compression tablet method,
The first step correctly takes by weighing each former, adjuvant according to the component dosage that prescription requires, and adds up to weight 305g;
Second step was ground breviscapine, crossed 100 mesh sieves; Mannitol, partially pregelatinized starch (kind reaching), lactose are respectively at 45 ℃ of oven dry, and it is standby that pulverizing is crossed 100 mesh sieves;
Adjuvants such as the 3rd step breviscapine and partially pregelatinized starch, crospolyvinylpyrrolidone, lactose, Fructus Citri Limoniae essence, aspartame, micropowder silica gel, magnesium stearate are with the equivalent method mix homogeneously that progressively increases, mistake 100 mesh sieves, evenly be divided into two parts standby;
The 4th step sodium bicarbonate and citric acid is respectively at 45 ℃ of oven dry, and pulverizing is crossed 100 mesh sieves, mix with portion in above-mentioned two parts of powder respectively make even;
The 5th step was used 65～75% alcohol granulation respectively with above two parts of mixed materials, oven dry below 40 ℃, and granulate adopts THP flower basket type tablet machine and diameter 8mm punch die tabletting, makes 1000 altogether, and every heavy 305mg contains breviscapine 20mg.
Embodiment 6
Component:
Raw material---breviscapine 20g;
Diluent---mannitol 100g, crospolyvinylpyrrolidone 10g, lactose 60g;
Disintegrating agent---partially pregelatinized starch (kind reaching) 8.5g;
Effervescent---sodium bicarbonate 20g, fumaric acid 16g;
Fluidizer---micropowder silica gel 10g;
Correctives---Fructus Citri Limoniae essence 5g; Aspartame 1.5g;
Lubricant---magnesium stearate 4g.
Adopt the preparation of wet granule compression tablet method,
The first step correctly takes by weighing each former, adjuvant according to the component dosage that prescription requires, and adds up to weight 255g;
Second step was ground breviscapine, crossed 100 mesh sieves; Mannitol, partially pregelatinized starch (kind reaching), lactose are respectively at 45 ℃ of oven dry, and it is standby that pulverizing is crossed 100 mesh sieves;
Adjuvants such as the 3rd step breviscapine and partially pregelatinized starch, crospolyvinylpyrrolidone, lactose, Fructus Citri Limoniae essence, aspartame, micropowder silica gel, magnesium stearate are with the equivalent method mix homogeneously that progressively increases, mistake 100 mesh sieves, evenly be divided into two parts standby;
The 4th step sodium bicarbonate and fumaric acid is respectively at 45 ℃ of oven dry, and pulverizing is crossed 100 mesh sieves, mix with portion in above-mentioned two parts of powder respectively make even;
The 5th step was used 65～75% alcohol granulation respectively with above two parts of mixed materials, oven dry below 40 ℃, and granulate adopts THP flower basket type tablet machine and diameter 8mm punch die tabletting, makes 1000 altogether, and every heavy 255mg contains breviscapine 20mg.
Embodiment 7
Component:
Raw material---breviscapine 20g;
Diluent---mannitol 100g, crospolyvinylpyrrolidone 10g, lactose 60g;
Disintegrating agent---partially pregelatinized starch (kind reaching) 8.5g;
Effervescent---sodium bicarbonate 20g, tartaric acid 16g;
Fluidizer---micropowder silica gel 10g;
Correctives---Fructus Citri Limoniae essence 5g; Aspartame 1.5g;
Lubricant---magnesium stearate 4g.
Adopt the preparation of wet granule compression tablet method,
The first step correctly takes by weighing each former, adjuvant according to the component dosage that prescription requires, and adds up to weight 255g;
Second step was ground breviscapine, crossed 100 mesh sieves; Mannitol, partially pregelatinized starch (kind reaching), lactose are respectively at 45 ℃ of oven dry, and it is standby that pulverizing is crossed 100 mesh sieves;
Adjuvants such as the 3rd step breviscapine and partially pregelatinized starch, crospolyvinylpyrrolidone, lactose, Fructus Citri Limoniae essence, aspartame, micropowder silica gel, magnesium stearate are with the equivalent method mix homogeneously that progressively increases, mistake 100 mesh sieves, evenly be divided into two parts standby;
The 4th step sodium bicarbonate and tartaric acid is respectively at 45 ℃ of oven dry, and pulverizing is crossed 100 mesh sieves, mix with portion in above-mentioned two parts of powder respectively make even;
The 5th step was used 65～75% alcohol granulation respectively with above two parts of mixed materials, oven dry below 40 ℃, and granulate adopts THP flower basket type tablet machine and diameter 8mm punch die tabletting, makes 1000 altogether, and every heavy 255mg contains breviscapine 20mg.
Embodiment 8
Component:
Raw material---breviscapine 20g;
Diluent---mannitol 100g, crospolyvinylpyrrolidone 10g, lactose 50g;
Disintegrating agent---partially pregelatinized starch (kind reaching) 8.5g;
Effervescent---sodium bicarbonate 20g, vitamin C 16g;
Fluidizer---micropowder silica gel 10g;
Correctives---Fructus Citri Limoniae essence 5g; Aspartame 1.5g;
Lubricant---magnesium stearate 4g.
Adopt the preparation of wet granule compression tablet method,
The first step correctly takes by weighing each former, adjuvant according to the component dosage that prescription requires, and adds up to weight 255g;
Second step was ground breviscapine, crossed 100 mesh sieves; Mannitol, partially pregelatinized starch (kind reaching), lactose are respectively at 45 ℃ of oven dry, and it is standby that pulverizing is crossed 100 mesh sieves;
Adjuvants such as the 3rd step breviscapine and partially pregelatinized starch, crospolyvinylpyrrolidone, lactose, Fructus Citri Limoniae essence, aspartame, micropowder silica gel, magnesium stearate are with the equivalent method mix homogeneously that progressively increases, mistake 100 mesh sieves, evenly be divided into two parts standby;
The 4th step sodium bicarbonate and vitamin C is respectively at 45 ℃ of oven dry, and pulverizing is crossed 100 mesh sieves, mix with portion in above-mentioned two parts of powder respectively make even;
The 5th step was used 65～75% alcohol granulation respectively with above two parts of mixed materials, oven dry below 40 ℃, and granulate adopts THP flower basket type tablet machine and diameter 8mm punch die tabletting, makes 1000 altogether, and every heavy 255mg contains breviscapine 20mg.
Claims (10)
1, a kind of oral cavity effervescent tablet for the treatment of the heart, cerebrovascular disease is characterized in that with the breviscapine being the primary raw material medicine, adds adjuvant diluent, disintegrating agent, effervescent, correctives, fluidizer and lubricant, and every each is former, adjuvant content is:
Raw material---breviscapine 20～40mg,
Diluent---20～100mg,
Disintegrating agent---2～40mg,
Effervescent---5～50mg,
Correctives---3～20mg,
Lubricant---2～10mg mg,
Fluidizer---5～10mg.
2,, it is characterized in that described diluent is monosaccharide such as pre-paying starch, cross-linked pvp, mannitol, lactose, disaccharidase, polysaccharide and wherein any one or two kinds of above mixture by the oral cavity effervescent tablet of the described treatment heart of claim 1, cerebrovascular disease.
3,, it is characterized in that described disintegrating agent is pre-paying starch, synthetic cellulose and wherein any one or two kinds of above mixture by the oral cavity effervescent tablet of the described treatment heart of claim 1, cerebrovascular disease.
4, by the oral cavity effervescent tablet of the described treatment heart of claim 1, cerebrovascular disease, it is characterized in that described effervescent is sodium bicarbonate and tartaric acid or citric acid or fumaric acid or Vitamin C mixture.
5,, it is characterized in that described correctives is that acesulfame potassium, A Siba are sweet, cyclamate and wherein any one or two kinds of above mixture by the oral cavity effervescent tablet of the described treatment heart of claim 1, cerebrovascular disease.
6,, it is characterized in that described lubricant is magnesium stearate, Pulvis Talci, sodium lauryl sulphate and wherein any one or two kinds of above mixture by the oral cavity effervescent tablet of the described treatment heart of claim 1, cerebrovascular disease.
7, by the oral cavity effervescent tablet of the described treatment heart of claim 1, cerebrovascular disease, it is characterized in that described fluidizer is micropowder silica gel.
8, by the oral cavity effervescent tablet of the described treatment heart of claim 1, cerebrovascular disease, it is characterized in that also can add adhesive, described adhesive comprises polysaccharose substance such as starch and cellulose substances such as HPMC.
9, the preparation method of the described oral cavity of claim 1 effervescent tablet is characterized in that adopting direct powder compression, undertaken by following step,
The first step is pressed recipe quantity, correctly takes by weighing each former, adjuvant;
Second step was dried back pulverizing, sieving for standby respectively with breviscapine and each diluent, effervescent;
The 3rd goes on foot effervescent respectively at oven dry below 45 ℃, sieving for standby behind the pulverizing;
The 4th step breviscapine and each adjuvant except that lubricant, fluidizer are with the equivalent method mix homogeneously that progressively increases;
The 5th step added lubricant and fluidizer, mix homogeneously, gained direct powder compression.
10, the preparation method of the described oral cavity of claim 1 effervescent tablet is characterized in that adopting the wet granule compression tablet method, undertaken by following step,
The first step is pressed prescribed dose, correctly takes by weighing each former, adjuvant;
Second step was dried back pulverizing, sieving for standby respectively with breviscapine and each diluent, effervescent;
The 3rd goes on foot effervescent respectively at oven dry below 45 ℃, sieving for standby behind the pulverizing;
The 4th step breviscapine and other each adjuvant except that effervescent are with the equivalent method mix homogeneously that progressively increases;
The 5th step was divided into two parts with above mixed material, respectively with sodium bicarbonate and sour mix homogeneously after, with the granulation of 65～75% ethanol, under 40～55 ℃ condition, dry, tabletting promptly behind the granulate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100165104A CN1321645C (en) | 2004-02-24 | 2004-02-24 | Oral effervesce tablets for treating cardiovascular and cerebrovascular diseases, and prepn. method therefor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100165104A CN1321645C (en) | 2004-02-24 | 2004-02-24 | Oral effervesce tablets for treating cardiovascular and cerebrovascular diseases, and prepn. method therefor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1559423A true CN1559423A (en) | 2005-01-05 |
| CN1321645C CN1321645C (en) | 2007-06-20 |
Family
ID=34440514
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100165104A Expired - Fee Related CN1321645C (en) | 2004-02-24 | 2004-02-24 | Oral effervesce tablets for treating cardiovascular and cerebrovascular diseases, and prepn. method therefor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1321645C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106265833A (en) * | 2016-08-01 | 2017-01-04 | 遵义医学院 | A kind of Flos Lonicerae effervescent tablet and preparation method thereof |
| CN109303334A (en) * | 2018-10-17 | 2019-02-05 | 汤臣倍健股份有限公司 | A kind of micro- effervescent tablet in oral cavity and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100344290C (en) * | 2002-11-29 | 2007-10-24 | 北京天衡药物研究院 | Breviscapine dispersing tablet and its prepn |
| CN100536829C (en) * | 2003-01-27 | 2009-09-09 | 清华大学 | Erigeron breviscapus oral caving fast disintegration tablet and its preparation method |
-
2004
- 2004-02-24 CN CNB2004100165104A patent/CN1321645C/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106265833A (en) * | 2016-08-01 | 2017-01-04 | 遵义医学院 | A kind of Flos Lonicerae effervescent tablet and preparation method thereof |
| CN109303334A (en) * | 2018-10-17 | 2019-02-05 | 汤臣倍健股份有限公司 | A kind of micro- effervescent tablet in oral cavity and preparation method thereof |
| WO2020078036A1 (en) * | 2018-10-17 | 2020-04-23 | 汤臣倍健股份有限公司 | Micro-effervescent buccal tablet and preparation method thereof |
| JP2022512020A (en) * | 2018-10-17 | 2022-02-01 | バイヘルス・カンパニー，リミテッド | Slightly effervescent buccal tablets and their preparation method |
| JP7141542B2 (en) | 2018-10-17 | 2022-09-22 | バイヘルス・カンパニー，リミテッド | Slightly effervescent buccal tablet and its preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1321645C (en) | 2007-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1222317C (en) | Quickly disintegrable compression-molded materials and process for producing the same | |
| CN1638803A (en) | Tablets quickly disintegrating in oral cavity | |
| CN1271276A (en) | Controlled release of drugs delivered by sublingual or buccal administration | |
| CN1271997C (en) | Oral disintegration tablets contg. p-acetaminophenol, and prepn. method therefor | |
| CN1302772C (en) | Orally disintegrated sodium ferulate tablet and its prepn process | |
| CN1254246C (en) | Oral disintegration tablet of silaenafil and its pharmaceutically receptible salt and its preparing method | |
| CN1269480C (en) | Orally disintegrating tablet of loratadine and its preparation method | |
| CN1943561A (en) | Oral disintegration tablet of prulifloxacin and its preparing method | |
| CN1915216A (en) | New usage of tandospirone and its derivative, and composition containing tandospirone | |
| CN1559423A (en) | Oral effervesce tablets for treating cardiovascular and cerebrovascular diseases, and prepn. method therefor | |
| CN1303990C (en) | Sodium ferulate oral disintegrating tablet and its preparation process | |
| CN101690720A (en) | Carteolol orally disintegrating tablets and preparation method thereof | |
| CN1297263C (en) | Calcium gluconate oral disintegrating tablet and its preparation process | |
| CN1429618A (en) | Erigeron breviscapus oral caving fast disintegration tablet and its preparation method | |
| CN1296045C (en) | Oral disintegration tablet of dihydroergotoxine and its derivatives and its preparing process | |
| CN1478467A (en) | Rapid disintegrate tablet in oral and its preparation method | |
| CN1237965C (en) | Oral disintegrating tablet of bambuterol hydrochloride and its preparation method | |
| CN1660078A (en) | Oral disintegration tablet of bergenin and compound bergenin and preparation method | |
| CN1267094C (en) | Orally disintegrating tablet of safflor yellow and its preparation process | |
| CN1634096A (en) | Notoginseng total saponin orally disintegrating tablet | |
| CN1618428A (en) | Cefadroxil oral disintegrant tablet, and its prepn. method | |
| CN1698668A (en) | Motherwort extract dispersed tablet and preparation method of motherwort extract | |
| CN1500491A (en) | Release-controlled oral Roxithromycin formulation | |
| CN1245168C (en) | Storax and baras camphor oral disintegration tablet and its preparing process | |
| CN1562209A (en) | 'Unique taste' disintegration tablet of oral cavity use and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |